Volk, V., Theobald, S. J., Danisch, S., Khailaie, S., Kalbarczyk, M., Schneider, A., Bialek-Waldmann, J., Kronke, N., Deng, Y., Eiz-Vesper, B., Dragon, A. C., von Kaisenberg, C., Lienenklaus, S., Bleich, A., Keck, J., Meyer-Hermann, M., Klawonn, F., Hammerschmidt, W., Delecluse, H. J., Munz, C., Feuerhake, F., and Stripecke, R.

PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations

Lévy Y., Lacabaratz C., Ellefsen-Lavoie K., Stöhr W., Lelièvre J.D., Bart P.A., Launay O., Weber J., Salzberger B., Wiedemann A., Surenaud M., Koelle D.M., Wolf H., Wagner R., Rieux V., Montefiori D.C., Yates N.L., Tomaras G.D., Gottardo R., Mayer B., Ding S., Thiébaut R., McCormack S., Chêne G., Pantaleo G.

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Moodie Z., Walsh S.R., Laher F., Maganga L., Herce M.E., Naidoo S., Hosseinipour M.C., Innes C., Bekker L.G., Grunenberg N., Mann P., Yu C., deCamp A.C., Miner M.D., Yates N.L., Heptinstall J., Mkhize N.N., Dintwe O., Frahm N., Cohen KW., Allen M., Hutter J., Wagner R., Pantaleo G., McElrath M.J., Tomaras G.D., Morris L., Montefiori D.C., Andersen-Nissen E., Gray G.E., Gilbert P.B., Kublin J.G.; NIAID HVTN 100 and HVTN 111 trial teams.

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials